Interestingly, additional studies have identified recurrent MET exon 14 skipping mutations in NSCLC and subsequent studies have demonstrated clinical efficacy of small molecule MET inhibitors such as capmatinib, tepotinib, crizotinib or cabozantanib for treatment of NS patients with these MET exon 14 skipping mutations [13–15]. Here, MET is linked to non-small cell lung carcinoma.